Drug Profile

JRF 102

Alternative Names: JRF-102

Latest Information Update: 22 Apr 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chengdu Jinrui Foundation Biotech
Class Antineoplastics
Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-met inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

22 Apr 2021 Discontinued - Preclinical for Cancer in China (unspecified route) (Chengdu Jinrui Foundation Biotech pipeline, April 2021)
29 Jul 2020 Preclinical trials in Cancer in China (unspecified route), prior to July 2020 (Chengdu Jinrui Foundation Biotech pipeline, July 2020)
29 Jul 2020 Chengdu Jinrui Foundation Biotech submits an IND application for Cancer, prior to July 2020 (Chengdu Jinrui Foundation Biotech pipeline, July 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com